Whatever your reason for reading about the AIDS 2024 conference, lenacapavir as PrEP together with questions about access, will be your headline news.
After presenting the PURPOSE 1 study – in which lenacapavir was shown to be 100% effective in cisgender women – lead investigator Linda-Gail Bekker referred to the results as “beyond wonderful”, including for generating data in pregnant and lactating women.
They were just as compelling for Winnie Byanyima, head of UNAIDS, who two days earlier in the opening ceremony, called for immediate plans for global access to lenacapavir PrEP, including in low- and middle-income countries, especially countries that took part in the research.
But the careful design of the PURPOSE 1 raised many more issues that were often missed in some of the rapid reports sent out as breaking news.
Read the full report by Simon Collins, HIV i-Base here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.